MARKET

ICAD

ICAD

Icad Inc
NASDAQ
1.630
0.000
0.00%
Opening 12:40 05/22 EDT
OPEN
1.630
PREV CLOSE
1.630
HIGH
1.730
LOW
1.610
VOLUME
76.09K
TURNOVER
0
52 WEEK HIGH
3.970
52 WEEK LOW
1.050
MARKET CAP
43.26M
P/E (TTM)
-17.8337
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ICAD last week (0513-0517)?
Weekly Report · 2d ago
ICAD Stock Earnings: icad Beats EPS, Beats Revenue for Q1 2024
icad just reported results for the first quarter of 2024. Icad reported earnings per share of -5 cents. The company reported revenue of $ million. This was better than the analyst estimate for revenue of -6 cents. Icad is a company that is expected to go public in 2024.
Investorplace · 05/15 15:52
Craig-Hallum Keeps Their Buy Rating on iCAD (ICAD)
TipRanks · 05/15 12:55
*ICAD Believes It Has Sufficient Cash Resources to Fund Its Planned Ops With No Need to Raise Additional Funding >ICAD
Dow Jones · 05/15 12:05
*ICAD Cash and Cash Equivalents Were $20.3M as of March 31 >ICAD
Dow Jones · 05/15 12:04
icad Q1 Adj $(0.05) Beats $(0.06) Estimate, Sales $4.95M Beat $4.44M Estimate
Icad reported quarterly sales of $ million which beat the analyst consensus estimate by percent. The company reported quarterly losses of per share which is a percent increase over the same period last year. The company beat the analyst consensus estimate of losses of $  per share.
Benzinga · 05/15 12:02
BRIEF-iCAD, Inc. Q1 Gross Profit USD 4.1 Million
Reuters · 05/15 12:00
ICAD REPORTS FINANCIAL RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2024
Reuters · 05/15 12:00
More
About ICAD
iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a woman’s breast anatomy from the mammogram image.

Webull offers iCAD Inc stock information, including NASDAQ: ICAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ICAD stock methods without spending real money on the virtual paper trading platform.